Scarica l'app Stockscreener
83.36
2.80%
-2.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$85.76
Aprire:
$85.82
Volume 24 ore:
991.13K
Relative Volume:
0.90
Capitalizzazione di mercato:
$4.43B
Reddito:
-
Utile/perdita netta:
$-38.99M
Rapporto P/E:
-27.82
EPS:
-2.9966
Flusso di cassa netto:
$-24.94M
1 W Prestazione:
+2.12%
1M Prestazione:
+2.20%
6M Prestazione:
+65.89%
1 anno Prestazione:
+77.97%
Intervallo 1D:
$82.90
$86.34
Intervallo di 1 settimana:
$77.33
$87.17
Portata 52W:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Nome
Soleno Therapeutics Inc
Settore
Industria
Telefono
650-213-8444
Indirizzo
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Confronta SLNO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
83.36 | 4.56B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-23 | Iniziato | TD Cowen | Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2024-12-02 | Reiterato | Robert W. Baird | Outperform |
| 2024-12-02 | Reiterato | Stifel | Buy |
| 2024-09-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-10 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-05 | Iniziato | Piper Sandler | Overweight |
| 2024-01-23 | Iniziato | Stifel | Buy |
| 2023-11-21 | Ripresa | Guggenheim | Buy |
| 2020-09-29 | Iniziato | Guggenheim | Buy |
| 2020-01-10 | Iniziato | Craig Hallum | Buy |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2018-02-13 | Reiterato | Maxim Group | Buy |
Mostra tutto
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
What is the long term forecast for Soleno Therapeutics Inc. stockInsider Accumulation Tracker - thegnnews.com
Soleno Therapeutics Inc. Chart Enters High Volatility ZoneAI Driven Buy Alert Trade Blueprint Released - metal.it
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% - Yahoo Finance
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going - Yahoo Finance
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results - ADVFN Brasil
Regression Model Predicts Rangebound Movement in Soleno Therapeutics Inc.High Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion - MSN
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q2 2025 Earnings Call Transcript - Insider Monkey
Soleno Therapeutics’ Earnings Call Highlights Success and Optimism - TipRanks
Stifel raises Soleno Therapeutics stock price target to $118 on strong launch - Investing.com Nigeria
Soleno Therapeutics price target raised to $120 from $115 at TD Cowen - TipRanks
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales By Investing.com - Investing.com South Africa
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales - Investing.com Australia
Earnings call transcript: Soleno Therapeutics beats Q2 2025 forecasts with strong revenue - Investing.com
Soleno Therapeutics Q2 2025: Key Contradictions in Time to Fill and Revenue Growth Expectations - AInvest
Soleno (SLNO) Q2 Revenue Jumps 30% - AOL.com
Soleno Therapeutics Reports Strong Q2 2025 Performance - TipRanks
Soleno Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Soleno Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand - TipRanks
Soleno (SLNO) Q2 Revenue Jumps 30% - The Motley Fool
SOLENO THERAPEUTICS INC SEC 10-Q Report - TradingView
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Soleno Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Soleno Therapeutics earnings beat by $0.55, revenue topped estimates - Investing.com Canada
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch By Investing.com - Investing.com South Africa
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch - Investing.com Nigeria
Soleno Therapeutics Q2 2025 Financial Results and VYKAT XR Launch Update - TradingView
Soleno Therapeutics Q2 net loss $4.7 mln - MarketScreener
Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q2 Revenue $32.7M, vs. FactSet Est of $25.1M - MarketScreener
Soleno Reports First Revenue Quarter: VYKAT XR Launch Draws 295 Prescribers in 90 Days - Stock Titan
When Will Soleno Therapeutics, Inc. (NASDAQ:SLNO) Become Profitable? - 富途牛牛
Is Soleno Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
When is Soleno Therapeutics Inc. stock expected to show significant growthDynamic investment opportunities - Jammu Links News
Is Soleno Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What makes Soleno Therapeutics Inc. stock price move sharplyHigh-impact investment strategies - Jammu Links News
What are analysts’ price targets for Soleno Therapeutics Inc. in the next 12 monthsUnmatched market gains - Jammu Links News
How does Soleno Therapeutics Inc. compare to its industry peersRealize exceptional returns through smart trading - Jammu Links News
What is the risk reward ratio of investing in Soleno Therapeutics Inc. stockCapitalize on momentum-driven investment opportunities - Jammu Links News
Should I hold or sell Soleno Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
What are the latest earnings results for Soleno Therapeutics Inc.Unlock powerful portfolio management tools - Jammu Links News
How does Soleno Therapeutics Inc. generate profit in a changing economyExplosive trading growth - Jammu Links News
Soleno Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What catalysts could drive Soleno Therapeutics Inc. stock higher in 2025Stay ahead with daily market updates - Jammu Links News
What analysts say about Soleno Therapeutics Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What machine learning models say about Soleno Therapeutics Inc.Fast Gaining Stock Screener Reports Released - metal.it
How Soleno Therapeutics Inc. stock performs during market volatilityWeekly Watchlist of High Movers Released - beatles.ru
Live Scanner Shows Breakout on Soleno Therapeutics Inc.Growth Based Investment Plan Guidance Highlighted - metal.it
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET - The Globe and Mail
What does SLNO's flat EPS in 2024 indicate for future growth? - AInvest
Soleno Therapeutics Inc Azioni (SLNO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):